CN107260755A - 治疗炎症的方法 - Google Patents

治疗炎症的方法 Download PDF

Info

Publication number
CN107260755A
CN107260755A CN201710354912.2A CN201710354912A CN107260755A CN 107260755 A CN107260755 A CN 107260755A CN 201710354912 A CN201710354912 A CN 201710354912A CN 107260755 A CN107260755 A CN 107260755A
Authority
CN
China
Prior art keywords
polymer
purposes according
biocompatible polymer
acrylate
styrene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710354912.2A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·P·哈恩
韦伊-塔伊·扬
文森特·J·卡波尼
托马斯·D·戈洛比什
罗伯特·H·巴特利特
胡迈拉·贝居姆·阿利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytosorbents Corp
Original Assignee
Cytosorbents Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosorbents Corp filed Critical Cytosorbents Corp
Publication of CN107260755A publication Critical patent/CN107260755A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28004—Sorbent size or size distribution, e.g. particle size
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
    • B01J20/28073—Pore volume, e.g. total pore volume, mesopore volume, micropore volume being in the range 0.5-1.0 ml/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
    • B01J20/28076—Pore volume, e.g. total pore volume, mesopore volume, micropore volume being more than 1.0 ml/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/305—Addition of material, later completely removed, e.g. as result of heat treatment, leaching or washing, e.g. for forming pores
    • B01J20/3064—Addition of pore forming agents, e.g. pore inducing or porogenic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2201/00—Foams characterised by the foaming process
    • C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
    • C08J2201/044—Elimination of an inorganic solid phase
    • C08J2201/0444—Salts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2207/00—Foams characterised by their intended use
    • C08J2207/10—Medical applications, e.g. biocompatible scaffolds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2325/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
    • C08J2325/02—Homopolymers or copolymers of hydrocarbons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201710354912.2A 2010-04-01 2011-04-01 治疗炎症的方法 Pending CN107260755A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31999310P 2010-04-01 2010-04-01
US61/319,993 2010-04-01
CN201180027139XA CN103037869A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180027139XA Division CN103037869A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Publications (1)

Publication Number Publication Date
CN107260755A true CN107260755A (zh) 2017-10-20

Family

ID=44712650

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710354912.2A Pending CN107260755A (zh) 2010-04-01 2011-04-01 治疗炎症的方法
CN201180027139XA Pending CN103037869A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180027139XA Pending CN103037869A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Country Status (9)

Country Link
US (6) US9717755B2 (cg-RX-API-DMAC7.html)
EP (2) EP3384916A1 (cg-RX-API-DMAC7.html)
JP (2) JP6073778B2 (cg-RX-API-DMAC7.html)
CN (2) CN107260755A (cg-RX-API-DMAC7.html)
AU (1) AU2011234978B2 (cg-RX-API-DMAC7.html)
CA (1) CA2795177C (cg-RX-API-DMAC7.html)
ES (1) ES2686545T3 (cg-RX-API-DMAC7.html)
MX (1) MX342421B (cg-RX-API-DMAC7.html)
WO (1) WO2011123767A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107260755A (zh) * 2010-04-01 2017-10-20 西托索尔本茨公司 治疗炎症的方法
JP6049685B2 (ja) 2011-03-23 2016-12-21 ネクステージ メディカル インコーポレイテッド 腹膜透析使い捨てユニット、コントローラ、腹膜透析システム
US9861733B2 (en) 2012-03-23 2018-01-09 Nxstage Medical Inc. Peritoneal dialysis systems, devices, and methods
EP2679302A1 (de) 2012-06-28 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Selektives Sorptionsmittel für die extrakorporale Blutreinigung
US20150335576A1 (en) * 2012-06-29 2015-11-26 Cytosorbents Corporation Methods of using polymers
US10639405B2 (en) 2014-07-22 2020-05-05 Asahi Kasei Medical Co., Ltd. Adsorbent for removing histone and purification device for liquid derived from living organism
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
US20190060545A1 (en) * 2016-03-08 2019-02-28 Cytosorbents Corporation The use of a hemocompatible porous polymer bead sorbent for removal of pamps and damps
RU2018146119A (ru) 2016-05-26 2020-06-26 Сайтосорбентс Корпорейшн Использование гемосовместимого сорбента из пористых полимерных шариков для удаления вызывающих эндотоксикоз молекул
EP3630325A4 (en) 2017-05-23 2021-02-17 Cytosorbents Corporation METHODS FOR TREATMENT OF TRAUMATIC BRAIN INJURY
WO2018237375A1 (en) 2017-06-24 2018-12-27 Nxstage Medical, Inc. Peritoneal dialysis fluid preparation and/or treatment devices methods and systems
MX2020002048A (es) * 2017-08-31 2020-09-21 Cytosorbents Corp Reduccion de productos finales de glicacion avanzada a partir de fluidos corporales.
CA3092575A1 (en) 2018-02-28 2019-09-06 Nxstage Medical, Inc. Fluid preparation and treatment devices, methods, and systems
CA3118792A1 (en) 2018-11-16 2020-05-22 Hemanext Inc. Methods for managing adverse events in patients with inflammation
WO2021034773A1 (en) * 2019-08-16 2021-02-25 Cytosorbents Corporation Methods for improving bone fracture healing
JP7614656B2 (ja) 2019-09-30 2025-01-16 ヘモチューン アーゲー 体液の体外処理のためのアセンブリ
EP4135749A4 (en) * 2020-04-14 2024-04-17 Cytosorbents Corporation IMPROVED IMMUNE RESPONSE AND REDUCED IMMUNOPARALYSIS WITH IMMUNOMODULATOR TREATMENT
JP2023539106A (ja) * 2020-08-19 2023-09-13 サイトソーベンツ・コーポレーション 治療的および美容的な創傷処置法
CN118613294A (zh) * 2021-11-29 2024-09-06 西托索尔本茨公司 经改善的癌症免疫疗法治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119576A1 (en) * 2006-11-20 2008-05-22 Wei-Tai Young Size-selective hemoperfusion polymeric adsorbents
US20080138434A1 (en) * 1997-07-30 2008-06-12 Medasorb Corporation Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US20100074954A1 (en) * 2002-11-01 2010-03-25 Kureha Chemical Industries Co., Ltd. Adsorbent for oral administration

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213165B (en) * 1993-05-11 1997-02-28 Bot Process to prepare biopolymers with detoxicating activity
US20020197250A1 (en) 2001-04-10 2002-12-26 Renal Tech International Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
CN1136042C (zh) * 1998-01-06 2004-01-28 塞鲁斯公司 降低生物组合物中化合物的流动式设备和使用方法
US20020197252A1 (en) 2001-04-10 2002-12-26 Renal Tech International Selective adsorption devices and systems
JP3672200B2 (ja) 2002-11-01 2005-07-13 呉羽化学工業株式会社 経口投与用吸着剤
TWI370012B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
WO2005115336A2 (en) * 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
WO2006044577A1 (en) 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
US20060228416A1 (en) 2005-04-06 2006-10-12 Marie-Pierre Faure Methods for modulating topical inflammatory response
EP1842545A1 (en) * 2006-04-04 2007-10-10 Marinomed Biotechnologie GmbH Anti-inflammatory polymer
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
CN101307149B (zh) 2008-05-30 2011-06-01 珠海健帆生物科技股份有限公司 一种医用吸附剂载体的制备方法
EP2352568B1 (en) * 2008-10-02 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Administration of an adsorbent polymer for treatment of systemic inflammation
US8923172B2 (en) * 2009-08-24 2014-12-30 Qualcomm Incorporated Deterministic backoff channel access
CN107260755A (zh) * 2010-04-01 2017-10-20 西托索尔本茨公司 治疗炎症的方法
US10064406B2 (en) 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138434A1 (en) * 1997-07-30 2008-06-12 Medasorb Corporation Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US20100074954A1 (en) * 2002-11-01 2010-03-25 Kureha Chemical Industries Co., Ltd. Adsorbent for oral administration
US20080119576A1 (en) * 2006-11-20 2008-05-22 Wei-Tai Young Size-selective hemoperfusion polymeric adsorbents

Also Published As

Publication number Publication date
EP2552459A1 (en) 2013-02-06
US20130195792A1 (en) 2013-08-01
JP2016175914A (ja) 2016-10-06
US20160279163A1 (en) 2016-09-29
EP2552459B1 (en) 2018-07-18
CA2795177A1 (en) 2011-10-06
US20170296574A1 (en) 2017-10-19
US20210330697A1 (en) 2021-10-28
AU2011234978B2 (en) 2016-03-17
JP2013523772A (ja) 2013-06-17
US10034894B2 (en) 2018-07-31
US9717755B2 (en) 2017-08-01
MX2012011305A (es) 2013-01-29
US11058715B2 (en) 2021-07-13
EP3384916A1 (en) 2018-10-10
CN103037869A (zh) 2013-04-10
US10967001B2 (en) 2021-04-06
US20180311273A1 (en) 2018-11-01
JP6073778B2 (ja) 2017-02-01
EP2552459A4 (en) 2013-12-25
MX342421B (es) 2016-09-28
ES2686545T3 (es) 2018-10-18
CA2795177C (en) 2018-07-03
WO2011123767A1 (en) 2011-10-06
US20190282608A1 (en) 2019-09-19
US10946040B2 (en) 2021-03-16
AU2011234978A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
US10946040B2 (en) Method of treating inflammation
Fry Sepsis syndrome
JP6945607B2 (ja) ポリマーの使用法
EP2352568B1 (en) Administration of an adsorbent polymer for treatment of systemic inflammation
JP2011225593A (ja) 心肺バイパス（ｃｐｂ）手術の術後合併症を低減するための組成物
CN1057937C (zh) 溶菌酵素二聚体的新用途及其含有溶菌酵素二聚体的制剂
RU2048811C1 (ru) Способ повышения эффективности антибиотикотерапии
Krishnaswamy et al. Moraxella catarrhalis induces mast cell activation and nuclear factor kappa B-dependent cytokine synthesis
CN121154829A (zh) 甘油磷脂和磷脂酶a2抑制剂联合用于治疗急性肺损伤和脓毒症
RU2033800C1 (ru) Способ лечения эрозивного эзофагита
CN120204397A (zh) 单核细胞抑制剂在制备治疗胆道闭锁药物中的应用
WO2017181371A1 (zh) 贻贝粘蛋白产品及其抑制脏器炎症的应用
JP2006335678A (ja) 改良されたブロメライン製剤およびそれを含む医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20171020